NEXI — Neximmune Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.01m
- -$2.41m
Annual income statement for Neximmune, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 20.9 | 27.9 | 52.4 | 63.1 | 33.1 |
| Operating Profit | -20.9 | -27.9 | -52.4 | -63.1 | -33.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -20.5 | -29.9 | -50.9 | -62.5 | -32.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -20.5 | -29.9 | -50.9 | -62.5 | -32.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -20.5 | -29.9 | -50.9 | -62.5 | -32.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.2 | -33.1 | -51.3 | -62.5 | -32.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -26.9 | -38.5 | -64.6 | -65 | -27.1 |
| Dividends per Share |